CDC/HHS on aspirin
This article was originally published in The Tan Sheet
Executive SummaryDiscussion of daily aspirin use between a physician and an at-risk adult "is one of the most valuable preventive services that can be offered in medical practice today," according to a May 16 report by the Partnership for Prevention. "Priorities for America's Health: Capitalizing on Life-Saving, Cost-Effective Preventive Services" was funded by HHS, the Centers for Disease Control & Prevention, and the Agency for Healthcare Research & Quality. Researchers analyzed more than 8,000 published studies and ranked preventive services according to two criteria: disease, injury, and death prevented if the service were delivered to all the people who would benefit from it, and cost effectiveness. Discussion of daily aspirin use topped the list along with immunizations of children and intervening with smokers to convince them to quit. The report calls aspirin "one of the most underused important interventions" and states that if physicians advised all high-risk adults to consider daily aspirin therapy, 80,000 lives could be saved annually with a net medical cost savings of $70 per person. The report is slated for publication in the July American Journal of Preventive Medicine...
You may also be interested in...
Stephen Hahn, the Trump administration’s nominee to lead the US FDA, has been approved by the Senate Health, Education, Labor and Pensions (HELP) Committee, with some “no votes” from Democratic senators in leadership positions, and is expected to be considered by the full Senate this week.
The US agency will host a two-day meeting to discuss the evolution of artificial intelligence technology used to analyze radiological images when diagnosing patients and in advising radiologists to take optimal pictures. The takeaways from the meeting will be used by the FDA to help it develop its thinking on how to regulate such technology.
ArQule's lead candidate, ARQ 531, is a novel BTK inhibitor in Phase II development that could work in patients with B-cell malignancies resistant to existing BTK inhibitors like Imbruvica.